Seelos Therapeutics, Inc. (NASDAQ:SEEL) Short Interest Update

Seelos Therapeutics, Inc. (NASDAQ:SEEL) was the recipient of a significant growth in short interest in July. As of July 15th, there was short interest totalling 295,000 shares, a growth of 116.8% from the June 30th total of 136,100 shares. Currently, 10.9% of the company’s shares are sold short. Based on an average trading volume of 488,800 shares, the short-interest ratio is currently 0.6 days.

Seelos Therapeutics Stock Down 6.6 %

NASDAQ:SEEL traded down $0.03 during midday trading on Friday, hitting $0.44. The stock had a trading volume of 298,842 shares, compared to its average volume of 1,329,906. The stock has a 50-day moving average of $0.85 and a 200 day moving average of $4.14. Seelos Therapeutics has a one year low of $0.43 and a one year high of $398.40.

Seelos Therapeutics (NASDAQ:SEEL) last issued its earnings results on Tuesday, May 14th. The company reported ($1.60) earnings per share (EPS) for the quarter. The business had revenue of $0.58 million for the quarter.

Institutional Trading of Seelos Therapeutics

An institutional investor recently raised its position in Seelos Therapeutics stock. Wealth Effects LLC boosted its stake in shares of Seelos Therapeutics, Inc. (NASDAQ:SEEL) by 104.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 466,660 shares of the company’s stock after purchasing an additional 238,067 shares during the quarter. Wealth Effects LLC owned about 3.41% of Seelos Therapeutics worth $276,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 23.37% of the company’s stock.

Seelos Therapeutics Company Profile

Seelos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD).